Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis

Although most immune-related adverse events (irAEs) secondary to immune checkpoint inhibitors can be managed with immunosuppressive therapies; they can induce reactivation of infectious diseases, including cytomegalovirus (CMV). Here, we show a case of CMV enterocolitis during steroid therapy for an...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuta, Yoki, Miyamoto, Hideaki, Naoe, Hideaki, Shimoda, Miki, Hinokuma, Yukari, Miyamura, Tomohiro, Miyashita, Azusa, Fukushima, Satoshi, Tanaka, Motohiko, Sasaki, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098339/
https://www.ncbi.nlm.nih.gov/pubmed/32231510
http://dx.doi.org/10.1159/000506186
Descripción
Sumario:Although most immune-related adverse events (irAEs) secondary to immune checkpoint inhibitors can be managed with immunosuppressive therapies; they can induce reactivation of infectious diseases, including cytomegalovirus (CMV). Here, we show a case of CMV enterocolitis during steroid therapy for an irAE. A 77-year-old man with unresectable malignant melanoma was treated with ipilimumab. He suffered from immune-related colitis (irColitis) and was treated with methylprednisolone. Although corticosteroids initially improved his symptoms, CMV reactivation occurred and colitis was exacerbated. Antiviral therapy improved his symptoms without augmenting the immunosuppressive therapy. CMV colitis should be considered when a patient with irColitis shows resistance to immunosuppressive therapy.

Ejemplares similares